In particular, as HER2 positivity is considered a positive prognostic factor for BC patients with BM and, in some cases with expected good prognosis, delay of local treatment is now being proposed by guidelines, an adequate prediction of outcome for these patients is even more crucial for treatment planification [3]. This evidence concerns the gene ERBB2 and breast cancer.